Clinical Pathology, Center of Molecular Medicine, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.
Department of Emergency and Organ Transplantation-Nephrology, Dialysis and Transplantation Unit, University of Bari Aldo Moro, 70124 Bari, Italy.
Cells. 2021 Sep 15;10(9):2426. doi: 10.3390/cells10092426.
For decades, the complement system, the central pillar of innate immune response, was recognized as a protective mechanism against cancer cells and the manipulation of complement effector functions in cancer setting offered a great opportunity to improve monoclonal antibody-based cancer immunotherapies. Similarly, cellular senescence, the process of cell cycle arrest that allow DNA and tissue repair has been traditionally thought to be able to suppress tumor progression. However, in recent years, extensive research has identified the complement system and cellular senescence as two main inducers of tumour growth in the context of chronic, persistent inflammation named inflammaging. Here, we discuss the data describing the ambivalent role of senescence in cancer with a particular focus on tumors that are strongly dependent on complement activation and can be understood by a new, senescence-related point of view: prostate cancer and renal cell carcinoma.
几十年来,补体系统一直被认为是先天免疫反应的核心支柱,是抵抗癌细胞的保护机制,而在癌症环境中操纵补体效应功能则为改善基于单克隆抗体的癌症免疫疗法提供了绝佳机会。同样,细胞衰老作为一种允许 DNA 和组织修复的细胞周期停滞过程,传统上被认为能够抑制肿瘤的进展。然而,近年来,大量研究已经确定补体系统和细胞衰老作为慢性、持续性炎症(即炎症老化)环境下肿瘤生长的两个主要诱导因素。在这里,我们讨论了描述衰老在癌症中双重作用的相关数据,特别关注强烈依赖补体激活的肿瘤,并可以通过一个新的、与衰老相关的观点来理解:前列腺癌和肾细胞癌。